Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • About HHS
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations
  • Radical Transparency
  • Big Wins
Breadcrumb
  1. Home
  2. About
  3. Budget
  4. Food and Drug Administration
  • HHS Family of Agencies
    • HHS Agencies & Offices
    • Regional Offices
    • Advisory Committees, Task Forces & Initiatives
    • Organizational Chart
  • Leadership
  • Budget & Performance
    • FY 2025 Contingency Staffing Plan
    • FY 2025 Budget in Brief
    • FY 2025 Annual Performance Plan and Report
    • FY 2024 Contingency Staffing Plan
    • FY 2024 Annual Performance Plan and Report
    • FY 2023 Contingency Staffing Plan
    • FY 2023 Annual Performance Plan and Report
    • FY 2022 Contingency Staffing Plan
    • FY 2022 Annual Performance Plan and Report
    • FY 2021 Contingency Staffing Plan
    • FY 2021 Annual Performance Plan and Report
    • FY 2020 Contingency Staffing Plan
    • FY 2020 Annual Performance Report
  • Press Room
  • I Am HHS
  • Careers

Food and Drug Administration

Topics on this page: Summary of Activities that Continue | Summary of Contingency Staffing Plan


Summary of Activities that Continue

The Food and Drug Administration (FDA) activities funded through user fees will continue including the regulation and testing of human and animal drugs, biosimilars, medical devices, and tobacco products. User fee work specifically supports the approval of new medical products, the review of requests to conduct important clinical research, the issuance of guidance, and other necessary activities to help patients have access to new therapies and important generic and biosimilar treatment options.

All vital FDA activities related to imminent threats to human health or life will also continue. This includes detecting and responding to public health emergencies, continuing to address existing critical public health challenges, and managing recalls, including drug shortages, and outbreaks related to foodborne illness and infectious diseases.  Other vital activities that will continue are surveillance of adverse event reports for issues that could cause human harm, the review of import entries to determine potential risks to human health, determining conduct for cause and surveillance inspections of regulated facilities, and criminal enforcement work and certain civil investigations.

Summary of Contingency Staffing Plan

In the event of a lapse of appropriation, 13,133 (75%) of FDA staff will be retained including 9,017 (52%) who are exempt (their activities or position are already funded or otherwise exempted) and 4,116 (24%) who are excepted (their activities are deemed necessary by implication, or for the safety of human life or protection of property).

Exempt Staff:

A total of 9,017 (52%) FDA staff will be exempt. Exempt FDA staff include one HHS Officer appointed by the President and 9,016 staff who support activities that have funding available during a lapse in appropriations. These activities with funding available include user fee programs including the approval of new medical products, the ability to review requests to conduct important clinical research, issue guidance, and conduct other necessary activities to help patients have access to new therapies and important generic and biosimilar treatment options.

Excepted Staff:

A total of 4,116 (24%) FDA staff are considered excepted and can legally continue their activities in the absence of appropriations. These staff fall into three categories; 1) those whose work is necessary for the safety of human life, 2) those whose work is necessary for the protection of property, and 3) those whose work is "necessarily implied" from the authorized continuation of other activities or the need to phase down and suspend operations.

Excepted FDA staff will continue to perform vital tasks related to imminent threats to human health or life including detecting and responding to emergencies, managing recalls, pursuing criminal enforcement work and certain civil investigations, reviewing import entries to determine potential risks to human health, conducting for cause and surveillance inspections of regulated facilities, conducting surveillance of adverse events reports for issues that could cause human harm, and other critical public health issues as appropriate. These excepted staff will also be responsible for continuing efforts to address other serious public health challenges, including drug shortages, and outbreaks related to foodborne illness and infectious diseases.

Excepted staff will also continue activities ensuring the protection of government research property, animals, and inanimate property. Examples include the care and feeding of any animals associated with research activities and maintaining research property used for regulatory science research such as high performance computational equipment.

Additionally staff will also be considered exempt and continue to work if their duties are necessary to ensure the ongoing support and operations of funded activities, or if they are needed for the orderly phase down and suspension of non-funded activities. These FDA staff will continue to provide the necessary operational support to ensure the centers and offices can continue authorized and funded activities. For example, user fee work that supports the approval of new medical products (for both humans and animals), the ability to review requests to conduct important clinical research, issue guidance, and other necessary activities to help patients have access to new therapies and important generic and biosimilar treatment options.


<< FY 2020 HHS Contingency Staffing Plan

Top of page

FY 2020 Lapse Plan Health Resources and Services Administration (HRSA) >>

Content created by Office of Budget (OB)
Content last reviewed November 18, 2019
Back to top

Subscribe to Email Updates

Receive the latest updates from the Secretary and Press Releases.

Subscribe
  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • Press Room
  • HHS Archive
  • Accessibility Statement
  • Privacy Policy
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy
HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​

Follow HHS

Follow Secretary Kennedy